|
Cardiovascular Exchange Summit 2011
|
|
|
Atrial Fibrillation Demographics by Age
|
|
|
AF – an epidemic
|
|
|
AF Increases Mortality
|
|
|
Hospitalisation Rates Among AF Patients
|
|
|
AF treatment - Stroke Prevention
& Symptom Management
|
|
|
Control of Ventricular Rate in Atrial Fibrillation
|
|
|
Impact of Drug Therapy on Exercise Ventricular Rate in Atrial Fibrillation
|
|
|
Vaughan Williams Classification of Antiarrhythmic Drugs
|
|
|
Rhythm control for AF-Duration and Cardioversion
|
|
|
Atrial Fibrillation-Antiarrhythmic Therapy
|
|
|
AADs for AF
|
|
|
Dronedarone
|
|
|
ESC Guidelines for Paroxysmal AF Management
|
|
|
Dronedarone - NICE Guidance
|
|
|
Rate vs Rhythm control-AFFIRM - all-cause mortality
|
|
|
AFFIRM - Prevalence of SR at follow-up
|
|
|
Non-pharmacological AF Treatment Options
|
|
|
Outcome After AVN Ablation and Pacing
|
|
|
The Pulmonary Vein Potential
|
|
|
Location of Triggering Foci
|
|
|
Initiating and Maintaining Atrial Fibrillation
|
|
|
Progression of paroxysmal to persistent AF-HATCH Score
|
|
|
AF ablation - randomised trials
|
|
|
AF ablation – heart failure pts
|
|
|
AF – Stroke prevention
|
|
|
CHA2DS2VASc Score
|
|
|
Efficacy of Warfarin Compared with Control for the Prevention of Ischaemic Stroke
|
|
|
Beyond warfarin…
|
|
|
Dabigatran – RE-LY trial
|
|
|
Stroke prevention - Dabigatran
|
|
|
Anticoagulation in AF
|
|
|
AF – an evolving epidemic
|
|
Deel deze pagina met collega's en vrienden: